Hiroyuki Abe to Neoadjuvant Therapy
This is a "connection" page, showing publications Hiroyuki Abe has written about Neoadjuvant Therapy.
Connection Strength
0.466
-
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308.
Score: 0.170
-
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018 12; 289(3):618-627.
Score: 0.138
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 Nov; 196(1):57-66.
Score: 0.046
-
Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
Score: 0.044
-
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. J Magn Reson Imaging. 2019 06; 49(6):1617-1628.
Score: 0.035
-
Lymph node wire localization post-chemotherapy: Towards improving the false negative sentinel lymph node biopsy rate in breast cancer patients. Clin Imaging. 2018 Mar - Apr; 48:69-73.
Score: 0.033